MedTrace Logo

The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy

NCT02125981 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2023-04-14

No results posted yet for this study

Summary

The limaprost alfadex can improve the surgical outcomes in patients with cervical myelopathy.

Conditions

  • Cervical Myelopathy

Interventions

DRUG

Limaprost

taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day

DRUG

Placebo

taking placebo drug

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jin S. Yeom · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-01
Primary Completion
2022-10-01
Completion
2023-04-01

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02125981 on ClinicalTrials.gov